Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong
This article was originally published in The Tan Sheet
Executive Summary
GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.
You may also be interested in...
Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.
Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
Resveratrol Partners submitted a petition that argues FDA regulations slow the development of health care products to address public health needs, such as the treatment of wet age-related macular degeneration. “It’s the public’s welfare, it’s not about rules and regulations,” says the firm’s managing partner, Bill Sardi.
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Nutritional ingredient developer ChromaDex is employing a pharma-style business model to expand its R&D into finished dietary supplements – with a long-term eye on pharmaceutical products. The firm’s recent hire of CEO Jeffrey Himmel was a significant step into the consumer products arena.